ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 2618 • 2016 ACR/ARHP Annual Meeting

    Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)

    Jacques Morel1,2, Arnaud CONSTANTIN3, Gabriel Baron4, Emmanuelle Dernis5, Rene-Marc Flipo6,7, Stephanie Rist Bouillon8, Bernard Combe9, Jacques-Eric Gottenberg10, Thierry Schaeverbeke11,12, Martin Soubrier13, Olivier Vittecoq14, Maxime Dougados15, Alain Saraux16, Xavier Mariette17, Philippe Ravaud18 and Jean Sibilia19, 1Montpellier University Hospital, Montpellier, France, 2Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 3Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 4Hôpital Hôtel Dieu, Paris, France, 5Service de Rhumatologie, Centre Hospitalier, Le Mans, France, 6Rheumatology, Hopital R Salengro CHRU, Lille, France, 7Rheumatology, University Hospital, Lille, France, 8Rhumatologie, Hopital La Source, La Source, France, 9Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 10Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 11Bordeaux University Hospital, Bordeaux, France, 12Rheumatology, CHU Bordeaux, Bordeaux, France, 13Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 14Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 15Paris Descartes University, Paris, France, 16Rheumatology, Brest University Medical School Hospital, Brest, France, 17Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, 18Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, 19Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of…
  • Abstract Number: 1193 • 2016 ACR/ARHP Annual Meeting

    Mortality Rate According to Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis

    Khushboo Sheth1,2, Chia-Ling Kuo3, Dhruv Modi4 and Christopher Scola5, 1Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, 2Rheumatology, Stanford University, Palo Alto, CA, 3Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT, 4Internal Medicine, Jamaica Hospital and Medical Center, New York, NY, 5Rheumatology, Hartford Hospital, Hartford, CT

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of excessive immune activation associated with high mortality. Early diagnosis and treatment can reduce mortality among these patients.…
  • Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting

    Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database

    Tatsuya Atsumi1, Yoshiaki Ando2, Yukiko Hayashi2, Shinichi Matsuda2, Riwa Tanaka2, Nobuhiro Takagi2 and Ayako Nakasone2, 1Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Chugai Pharmaceutical Co. Ltd., Tokyo, Japan

    Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
  • Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting

    Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy

    Kevin L. Winthrop1, Yoshiya Tanaka2, Kunihiro Yamaoka3, Jeffrey R. Curtis4, Chudy Nduaka5, Haiyun Fan5, Pinaki Biswas6, Tomohiro Hirose7, Sriram Krishnaswami8, Hernan Valdez6, Shigeyuki Toyoizumi7, Koshika Soma8 and Connie Chen6, 1Oregon Health & Science University, Portland, OR, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Keio University, Tokyo, Japan, 4University of Alabama at Birmingham, Birmingham, AL, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, New York, NY, 7Pfizer Japan Inc, Tokyo, Japan, 8Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
  • Abstract Number: 2251 • 2015 ACR/ARHP Annual Meeting

    Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty

    Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To our knowledge, well-designed studies that have examined the risk of post-arthroplasty implant-related complications after TKA with tobacco use are lacking.  Our objective was…
  • Abstract Number: 2799 • 2015 ACR/ARHP Annual Meeting

    Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE

    Eliza F. Chakarvarty1, Jacy Odell2, Astrid Rasmussen3, Kathy L. Sivils2, Joel M. Guthridge2 and Judith A. James4, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Increasing data has suggested that individuals with systemic lupus (SLE) are at increased risk of herpes zoster (HZ) reactivation compared to healthy controls and…
  • Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting

    Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis

    Neil Accortt1, Jennifer Schenfeld2 and Mona Trivedi3, 1Amgen, Inc., Thousand Oaks, CA, 2Docs Global, Inc, North Wales, PA, 3Rheumatology, Amgen, Thousand Oaks, CA

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…
  • Abstract Number: 2817 • 2015 ACR/ARHP Annual Meeting

    The Microbiome of Reactive Arthritis in a Guatemalan Cohort

    Alexis Ogdie-Beatty1, Carles Ubeda2, Helga Raquel Garcia Ferrer3, Joan Von Feldt4, A Garcia Kutzbach5 and Jose U. Scher6, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Institute for Research in Public Health, Valencia, Spain, 3Society for Worldwide Med Exchange, North Bay Village, FL, 4University of Pennsylvania, Philadelphia, PA, 5Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, 6Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. Several agents microbial agents have been implicated, particularly Shigella, Salmonella, Campylobacter in the…
  • Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting

    Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib

    Nan Bing1, HuanYu Zhou1, BaoHong Zhang1, John D Bradley2, Makoto Nagaoka3, Hernan Valdez4, Michael Vincent1 and James D. Clark1, 1Pfizer Inc, Cambridge, MA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Tokyo, Japan, 4Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
  • Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting

    Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry

    Fabiola Atzeni1, Marco Sebastiani2, Valentina Panetta3, Fausto Salaffi4, Antonio Marchesoni5, Roberta Ramonda6, Florenzo Iannone7, Roberto Gorla8, Elisa Gremese9, Marcello Govoni10, Pier Carlo Sarzi-Puttini11, Gianfranco Ferraccioli12, Giovanni Lapadula13 and on behalf of GISEA group, 1Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, 2SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, 3L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, 4Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, 5Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, 6Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, 7Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, 8Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, 9Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 10Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, 11Rheumatology Unit, University Hospital L Sacco, Milan, Italy, 12Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, 13Bari University, Rheumatology, Bari, Italy

    Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of  rheumatoid arthritis (RA) and…
  • Abstract Number: 674 • 2015 ACR/ARHP Annual Meeting

    Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study

    Hirofumi Nishikawa1, Yoshinori Taniguchi1, Takashi Karashima2, Tetsushi Aita3, Susumu Nishiyama3, Yasuhiko Yoshinaga3, Yoshitaka Kumon4, Yoshiko Shimamura1, Kosuke Inoue1, Taro Horino1, Taro Shuin2 and Yoshio Terada1, 1Kochi University, Nankoku, Japan, 2Urology, Kochi University, Nankoku, Japan, 3Kurashiki Medical Center, Kurashiki, Japan, 4Chikamori Hospital, Kochi, Japan

    Background/Purpose: Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA)…
  • Abstract Number: 2899 • 2015 ACR/ARHP Annual Meeting

    Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France

    laurent chiche1, sarah malaekah2, alexandre belot3, Brigitte Bader-Meunier4, gregoire rey5, Noémie Jourde-Chiche Sr.6 and mireille eb5, 1internal medicine, Hopital Europeen, Marseille, France, 2pediatry, CHU Lyon, Lyon, France, 3Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, 4Hopital Necker-Enfants Malades, Paris, France, 5cepidc, paris, France, 6Nephrology, Aix-Marseille Université - APHM, Marseille, France

    Background/Purpose: Although regarded as a disease of adulthood, SLE is also seen in children, and is associated with an increased risk for aggressive clinical course…
  • Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting

    Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians

    Rebecca Sharim1, Leny Mathew2, Michael George3, Preethi Thomas4 and Misha Rosenbach5, 1Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, 5Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
  • Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting

    Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus

    Candace H. Feldman1, Francisco M. Marty2, Wolfgang C. Winkelmayer3, Hongshu Guan4, Jessica M. Franklin5, Seoyoung C. Kim6, Daniel H. Solomon7 and Karen H. Costenbader8,9, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, 3Medicine-Nephrology, Baylor College of Medicine, Houston, TX, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, 7Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 8Rheumatology, Brigham & Women's Hospital, Boston, MA, 9Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
  • Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting

    Mortality Due to Sepsis in Patients with Rheumatoid Arthritis

    Orit Barrett1, Ella Abramovich2, Jacob Dreiher3, Victor Novack4 and Mahmoud Abu-Shakra5, 1Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, 2Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, 3Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, 4Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, 5Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel

    Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to  identify the characteristics…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 36
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology